Preview

Медицинский Совет

Расширенный поиск

БИОЛОГИЧЕСКАЯ ТЕРАПИЯ И ИНФЕКЦИИ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ СОВРЕМЕННЫЕ АСПЕКТЫ

https://doi.org/10.21518/2079-701X-2016-11-106-116

Полный текст:

Аннотация

В последние десятилетия в ревматологии отмечается явный прогресс, связанный с внедрением в практику генно-инженерных биологических препаратов (ГИБП). В то же время применение этих препаратов ассоциируется с нарастающим риском развития инфекций разнообразной природы и локализации, включая оппортунистические (инвазивные микозы, пневмоцистная пневмония и др.), а также повышенный риск реактивации латентной инфекции, в первую очередь туберкулеза (ТБ). Помимо этого, регистрируются случаи тяжелых инфекций (пневмония, сепсис, бактериальный артрит, поражение кожи и мягких тканей и др.), в т. ч. с летальным исходом. В настоящем обзоре проанализированы данные литературы, преимущественно последних 5 лет, касающиеся частоты и локализации инфекций у больных ревматоидным артритом при лечении различными ГИБП. Охарактеризована значимость различных инфекций (ТБ, пневмонии, хронические вирусные гепатиты, герпес-вирусные инфекции и др.) в тактике курации указанных больных. Подчеркнута необходимость более широкого применения иммунизации различными вакцинами (в первую очередь пневмококковой и противогриппозной) пациентов с аутоиммунными воспалительными ревматическими заболеваниями.

Об авторах

Б. С. БЕЛОВ
Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия
д.м.н.


М. С. НАУМЦЕВА
Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия
к.м.н.


Г. М. ТАРАСОВА
Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия
д.м.н.


Д. В. БУХАНОВА
Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия


Список литературы

1. Wolfe F., Mitchell DM., Sibley JT. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37(4): 481-494.

2. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, Dougados M. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology. 2007; 46(2):327-334.

3. Kroesen S, Widmer AF, Tyndall A, Hasler P Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology. 2003; 42(5): 617-621.

4. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125-1133.

5. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum. 2007; 56(9):2896-2904.

6. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;50(1):124-131.

7. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403-3412.

8. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013; 52(1): 53-61.

9. Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J, et al. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(9):1667-73.

10. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Timedependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007; 66(10):1339-1344

11. Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG. et al. Long-term antiTNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225-9.

12. van Dartel SA, Fransen J, Kievit W, Dutmer EA, Brus HL, Houtman NM, et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology. 2013;52(6):1052-1057.

13. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, doubleblind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.. Ann Rheum Dis. 2015;74(3):538-46.

14. Keystone E, Genovese MC, Hall S, Miranda PC, Bae SC, Han C, Gathany T, Zhou Y, Xu S, Hsia EC . Five-year safety and efficacy of golimumab in patients with active rheumatoid arthritis despite prior treatment with methotrexate: final study results of the phase 3, randomized placebo-controlled go-forward trial. Ann Rheum Dis 2013;72 (Suppl 3):867-868.

15. Bykerk VP, Cush J, Winthrop K, Calabrese L, Lortholary O, de Longueville M, et al.. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015; 74(1): 96-103.

16. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54(9): 2793-2806.

17. Saag KG, Winthrop KL, Alexander K, Francom S, Furst DE. Long-term safety event rates in RA patients following initiation of rituximab: interim analysis fron SUNSTONE registry. Arthritis Rheum 2013; 65 (10 Suppl) 1002.

18. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology. 2011;50(1):222-229.

19. Gottenberg JE, Ravaud P, Cacoub P, Bardin T, Cantagrel AG, Combe B, et al.. The rate of serious infections remains stable in patients with multiple retreatments in real life: data from the “Autoimmunity and rituximab: (AIR) registry. Arthritis Rheum 2013; 65 (10 Suppl): 606-607.

20. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al.. Effects of abatacept in patients with methotrexateresistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-876.

21. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807-2816.

22. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial Ann Rheum Dis. 2007; 66(2):228-234.

23. Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013;40(6):787-797.

24. Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2016;75(6): 1108-13.

25. Baker N, Boers M, Hochberg M, Kawabata H, Ray N, Simon T. Risk of hospitalized infections in patients with rheumatoid arthritis initiating abatacept and other biologics: analysis of a United States claims database. Ann Rheum Dis 2016; 75(Suppl2): 516.

26. Sibilia J, Westhovens R. Safety of T-cell costimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007; (5 Suppl 46):46-56.

27. Smitten A, Simon T, Qi K, Franklin J, Askling J, Lacaille D, Suissa S, Hochberg MC. Hospitalized infections in the abatacept RA clinical development program: an updated epidemiological assessment with >10,000 person-years of exposure. Arthritis Rheum 2008; 58 (Suppl 9): 786-787.

28. Schiff MN Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology. 2013;52(6):986-997.

29. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5): R141

30. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198-205.

31. Morel J, Duzanski MO, Bardin T, Cantagrel AG, Combe B, Dougados M, et al. Prospective follow-up of tocilizumab treatment in 764 patients with refractory rheumatoid arthritis: tolerance and efficacy data from the French registry Regate (REGistry-RoAcTEmra. Arthritis Rheum 2012; 64(10 Suppl): 152.

32. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, et al. Long-term safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40(6):768-780.

33. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014 ;41(1):15-23.

34. Morel J, Constantin A, Dernis E, Rist S, Flipo RM, Schaeverbeke T et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with tocilizumab in the french registry regate (registry –RoActemra). Ann Rheum Dis 2016;75(Suppl2): 511.

35. Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, et al. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Mod Rheumatol. 2016; 14:1-10.

36. Iking-Konert C, von Hinüber U, Richter C et al. ROUTINE-a prospective, multicentre, noninterventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology (Oxford). 2016 Apr;55(4):624-35

37. Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology. 2011;50(3):552-562.

38. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009; 19(4):351-357.

39. Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, Suemura M. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol. 2009;19(1):64-68.

40. Burmester GR, Charles-Schloeman C, Isaacs JD, Hendrikx T, Kwok K, Zwillich SH, Riese R. Tofacitinib, an oral Janus kinase inhibitor: safety comparisonin patients with rheumatoid arthritis and an inadequate response to nonbiologic or biologic disease-modifying anti-rheumatic drugs. Arthritis Rheum 2013; 65(10 Suppl): 192.

41. Gomez-Reino J, Hazra A, Fosser C, Menon S, Zwillich SH, Riese R, Krishnaswami S. Post-hoc analysis of serious infection events and selected clinical factors in rheumatoid arthritis patients treated with tofacitinib. Arthritis Rheum 2013; 65(10 Suppl): 194

42. Fleischmann R, Kremer J, Tanaka Y, Gruben D, Kanik K, Koncz T,et al. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. Int J Rheum Dis. 2016. Published online Jul 25.

43. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K,et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in openlabel, longterm extension studies. J Rheumatol. 2014 May;41(5):837-52.

44. Wollenhaupt J, Silverfield J, Lee EB, Terry KK, Kwok K, Lazariciu I, et al. Tofacitinib, an oral jak inhibitor, in the treatment of rheumatoid arthritis: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years. Ann Rheum Dis 2016; 75(Suppl2): 252.

45. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al Adverse effects of biologics: a network metaanalysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD008794.

46. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, doubleblind, controlled phase 4 trial. Lancet. 2013; 381(9877): 1541-1550.

47. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-tohead comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86-94.

48. Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016; 388(10041): 239-47.

49. Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014 Dec;127(12):1208-32.

50. Bortoluzzi A, Sakellariou G, Carrara G, Govoni M, Scirè CA et al. Risk of hospitalization for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the record study of the Italian society for rheumatology Ann Rheum Dis 2016;75(Suppl2): 700.

51. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and metaanalysis. Lancet. 2015;386(9990): 258-65

52. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15): 1098-1104.

53. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48(8): 2122-2127.

54. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009; 60(7):1884-1894.

55. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010; 69(3): 522-528.

56. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ.. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and metaanalysis of randomized controlled trials and long-term extension studies. Rheumatology. 2014;53(10):1872-85.

57. Диагностика туберкулезной инфекции при планировании и проведении терапии блокаторами ФНО-α у больных ревматическими заболеваниями: Пособие для врачей. Ред. М.И. Перельман, Е.Л. Насонов. М., 2008. 40 с. [Diagnostics of tuberculosis infection at planning and performance of therapy by TNFalpha blockers in rheumatic diseases patients: Guide for doctors. Ed. by M.I. Perelman, E.L. Nasonov. M., 2008. 40 p].

58. Борисов С.Е., Лукина Г.В. Рекомендации по скринингу и мониторингу туберкулезной инфекции у больных, получающих генно-инженерные биологические препараты. Данные на сайте: www.rheumatolog.ru/files/natrec21/.pdf. Borisov S.E., Lukina G.V. Recommendations on screening and monitoring of tuberculosis infection in patients administering gene engineering biological drugs. Data on the web-site

59. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012; 66 (12): 1177-1181.

60. Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, Eisen SA.TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine. 2011; 90(2): 139-145.

61. Van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab: pooled analysis of the rheumatoid arthritis global clinical trial programm over 11 years. Arthritis Rheum 2013; 65(10 Suppl): 1000.

62. Hoshi D, Nakajima A, Inoue E, Shidara K, Sato E, Kitahama M, et al Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2012; 22(1):122-127.

63. Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. Arthritis Rheumatol. 2016; 68(1): 56-66.

64. Mori S., Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology. 2012;51(12):2120-2130.

65. Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, et al. Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. Mod Rheumatol. 2013; 23(6): 1085-1093.

66. Stamp LK, Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol. 2010;37(4):686-688.

67. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, SarziPuttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/antihepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010;62(6):749-754.

68. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011; 21(6):621-627.

69. Urata Y., Uesato R., Tanaka D., Kowatari K., Nitobe T., Nakamura Y., Motomura S. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21(1):16-23.

70. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31(8):1169-1175.

71. Vukatana G, Gamal N, Trevisani M, Cursaro C, Malavolta N, Andreone P.. Serological prevalence of hepatitis b virus infection among patients with different rheumatic diseases. Ann Rheum Dis 2013;72(Suppl3):310.

72. Lan JL1, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70(10):1719-25.

73. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol. 2003; 30(7):1624-1625.

74. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003; 62(7):686-687.

75. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011; 31(3): 403-404.

76. Ghrénassia E, Mékinian A, Rouaghe S, Ganne N, Fain O. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine. 2012; 79(1):100-101.

77. Gigi E, Georgiou T, Mougiou D, Boura P, Raptopoulou-Gigi M. Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia. 2013;17(1):91-93.

78. Salman-Monte TC, Lisbona MP, GarcíaRetortillo M, Maymó J. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin. 2014;10(3):196-7.

79. Vassilopoulos D, Delicha EM, Settas L, Andrianakos A, Aslanidis S, Boura P, et al. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.Clin Exp Rheumatol. 2016 Published online Jul 5.

80. Oshima Y, Tsukamoto H, Tojo A. Association of hepatitis B with antirheumatic drugs: a casecontrol study. Mod Rheumatol 2013;23(4):694-704.

81. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 Ann Rheum Dis. 2013;72 Suppl 2:2-34.

82. Kato M, Atsumi T. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention. Rheumatol Int. 2016;36(5):635-41.

83. Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine. 2014;81(6):478-84.

84. Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol. 2015;7(3):344-61.

85. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-1082.

86. Zein NN and Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomised, double-blind, placebo-controlled study. J Hepatol.2005; 42: 315-322.

87. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.

88. Inanc N, Direskeneli H. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int. 2006; 27(1):67-71.

89. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, Fraser VJ, Cunningham F, Eisen SA. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis Clin Infect Dis. 2009; 48(10):1364-1371.

90. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737-44.

91. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014;81(3):215-21.

92. Yun H., Xie F., Delzell E.S., Chen L., Levitan E., Lewis J, et al Comparative risk of Herpes zoster among RA patients switching biologics in the U.S. care medical program. Arthritis Rheum 2013; 65(10 Suppl): 1179.

93. Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(11):2924-37.

94. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL Real-world comparative risks of herpes virus infections in tofacitinib and biologictreated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Published online Apr 25.

95. Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2013;65(6): 854-61.

96. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies Arthritis Rheum. 2012;64(9):3043-3051.

97. Yamamoto M, Takahashi H, Wakasugi H, Sukawa Y, Saito M, Suzuki C, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol. 2007;17(1):72-4.

98. Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis. Intern Med. 2009; 48(15):1307-1309.

99. Ray M, Curtis JR, Baddley JW. A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis. 2014;73(7):1429-30.

100. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab the University of North Carolina at Chapel Hill. Arthritis Rheum 2010;62(11):3191-3195.

101. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-TNFα and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis Arthritis Care Res (Hoboken). 2014;66(7):1016-26.

102. Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Mörner A, Geborek P. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014;16(1): R2.

103. Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 2014;178(1):40-7.


Просмотров: 397


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)